Phase III IPATential150 study with RG 7440 plus Zytiga meets co-primary endpoint in prostate cancer.- Genentech/Roche
Genentech/Roche announced that the Phase III IPATential150 study with RG 7440 (ipatasertib) plus Zytiga (abiraterone) plus prednisone met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients… read more.